Skip to main content

Lucentis Disease Interactions

There are 2 disease interactions with Lucentis (ranibizumab ophthalmic).


Intravitreal injections (applies to Lucentis) ocular infections

Major Potential Hazard, High plausibility. Applicable conditions: Uveitis, Orbital Infection, Infectious Endophthalmitis, Infectious Optic Neuritis

Drugs requiring intravitreal administration (including aflibercept, faricimab, pegaptanib, and ranibizumab) are contraindicated in patients with active intraocular inflammation or ocular/periocular infections; intravitreal injections have been associated with endophthalmitis. Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive, or painful, or if a change in vision occurs in the days following drug administration.


  1. "Product Information. Macugen (pegaptanib ophthalmic)." OSI Pharmaceuticals Inc (2004):
  2. "Product Information. Lucentis (ranibizumab ophthalmic)." Genentech (2006):
  3. "Product Information. Eylea (aflibercept ophthalmic)." Regeneron Pharmaceuticals Inc (2011):
  4. "Product Information. Vabysmo (faricimab ophthalmic)." Genentech (2022):
View all 4 references

Ranibizumab intravitreal injection (applies to Lucentis) increased intraocular pressure

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Glaucoma/Intraocular Hypertension

Increases in intraocular pressure have been reported both pre- injection and post- injection (at 60 minutes) while being treated with ranibizumab. Intraocular pressure should be monitored prior and following intravitreal injection with ranibizumab and managed appropriately.


  1. "Product Information. Lucentis (ranibizumab ophthalmic)." Genentech (2006):

Lucentis drug interactions

There is 1 drug interaction with Lucentis (ranibizumab ophthalmic).

Report options

Share by QR Code
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.